The genome engineering company Cellectis S.A. (Alternext: ALCLS) and the pharmaceutical group Servier today announced the signature of a non-exclusive licensing agreement for the...
- Europe and International + 33 1 81 69 16 01
- USA and Canada + 1 617 682 3624